Evogene
EVGN
42 hedge funds and large institutions have $10M invested in Evogene in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 12 increasing their positions, 11 reducing their positions, and 6 closing their positions.
67% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 6
11% more funds holding
Funds holding: 38 → 42 (+4)
9% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 11
0.89% less ownership
Funds ownership: 15.53% → 14.63% (-0.89%)
40% less capital invested
Capital invested by funds: $16.7M → $10M (-$6.65M)
96% less call options, than puts
Call options by funds: $14K | Put options by funds: $361K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$325K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$307K |
| 3 |
EVC
Eidelman Virant Capital
Saint Louis,
Missouri
|
+$256K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$130K |
| 5 |
Jane Street
New York
|
+$115K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$947K |
| 2 |
Morgan Stanley
New York
|
-$437K |
| 3 |
JP Morgan Chase
New York
|
-$359K |
| 4 |
PP
PDT Partners
New York
|
-$204K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$182K |
EVGN Hedge Fund Activity: Q4 2021 in Review
42 of the 6,519 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q4 2021, worth a combined $10M — down 40% from $16.7M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new EVGN positions and 6 closed out — a net gain of 4 holders — while 12 added to existing stakes and 11 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $325K. The largest seller was ARK Investment Management, cutting an estimated $947K.
- 42 institutional investors held Evogene (EVGN) as of Q4 2021, up from 38 in Q3 2021.
- Funds reported $10M of Evogene stock for Q4 2021, down 40% quarter-over-quarter.
- 10 funds opened new Evogene positions in Q4 2021 and 6 closed out, a net change of +4 holders.
- The largest Evogene buyer in Q4 2021 was Millennium Management, an estimated $325K added.
- The largest Evogene seller in Q4 2021 was ARK Investment Management, an estimated $947K sold.
Based on aggregated 13F filings for Q4 2021.